Bifogade filer
SenzaGen expands regulatory testing portfolio – strengthens competitiveness and secures new orders
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SenzaGen has expanded its regulatory testing portfolio with EpiSensA, a new OECD-approved non-animal method for assessing whether chemicals can cause skin allergy upon contact. This expansion has already resulted in two new orders with a total value of approximately SEK 0.7 million. The tests will be conducted at the Group’s GLP-certified laboratory during the second and third quarters of 2025.
In March 2025, the SenzaGen Group implemented EpiSensA at its subsidiary VitroScreen in Milan, becoming the first company in the world to offer this method.
“By offering EpiSensA, we are broadening our customer offering and strengthening our position in non-animal regulatory testing. Our team has succeeded in being both first to market and in securing the first test orders within a very short time frame, which confirms customer demand and trust in our expertise and service,” says Peter Nählstedt, CEO and Group President of SenzaGen.
As regulatory authorities often require combinations of OECD-approved tests for skin sensitization when results are used for product registration, EpiSensA serves as an effective complement to SenzaGen’s existing portfolio. By focusing an earlier stage in the allergic skin reaction, the combination of EpiSensA and the company’s proprietary high-performing method GARD®skin becomes commercially attractive to SenzaGen’s customers.
EpiSensA (OECD TG 442D) is a 3D model-based method that examines the early response of skin cells to a chemical, while GARD®skin (OECD TG 442E) is based on genomics and machine learning to assess the later, critical stages when the immune system is activated.
For more information,
Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobil: 0700-23 44 31
Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobil: 0708-20 29 44
About SenzaGen AB (publ)
SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.